NeoGenomics overview after recent share performance

NeoGenomics (NEO) has drawn fresh attention after a mixed stretch in the stock, with a gain over the past month contrasting with a decline in the past 3 months and year to date.

The recent 30 day share price return of 11.82% follows earlier weakness, with the 90 day share price return down 5.60% and the 3 year total shareholder return down 45.53%. This suggests improving short term momentum after a tougher multi year stretch.

If you are weighing NeoGenomics against other opportunities in healthcare diagnostics and technology, this is a useful moment to scan for emerging healthcare AI ideas using the 34 healthcare AI stocks

With the stock up over the past year but still showing multi year weakness and trading well below analyst price targets, the key question is whether NeoGenomics is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 38.4% Undervalued

NeoGenomics last closed at $9.27, while the most followed narrative places fair value at $15.06, creating a wide gap that hinges on future execution and margins.

The commercial launch of PanTracer, a comprehensive liquid biopsy panel for therapy selection, is set to enhance NeoGenomics' competitiveness and capture greater share in the rapidly growing NGS and liquid biopsy segment, supporting revenue acceleration and higher average unit prices (AUP) through 2025 and beyond.

Curious what kind of revenue runway, margin shift, and future earnings multiple are baked into that fair value gap? The narrative leans on a specific growth path, richer test mix, and a premium valuation that many investors would usually associate with faster growing sectors.

Result: Fair Value of $15.06 (UNDERVALUED)

However, this depends on pharma and biotech demand stabilising, and competition in oncology diagnostics or any product or reimbursement setbacks could quickly challenge that upbeat narrative.

Another View: What The P/S Ratio Is Telling You

The analyst narrative leans on a future earnings rerating, but today NeoGenomics trades on a P/S of 1.6x, compared with 1.2x for the broader US Healthcare industry and 1x for peers, while the fair ratio is also 1.2x. That premium suggests investors are already paying up, so how comfortable are you with that valuation gap?

Next Steps

If the mixed signals here leave you uncertain, that is a good reason to act quickly and pressure test the downside for yourself using the 1 important warning sign

Looking for more investment ideas?

If NeoGenomics has caught your eye, do not stop here. Use the broader market as your hunting ground and let focused screeners surface fresh opportunities.

• Spot potential value by reviewing companies flagged as high quality but priced below what their fundamentals might justify using the 46 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with stronger balance sheets and sturdier fundamentals through the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by scanning a screener containing 22 high quality undiscovered gems before wider attention drives fresh interest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.